These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 29566415)

  • 41. Dosing of rivaroxaban by indication: getting the right dose for the patient.
    Escolar G; Carne X; Arellano-Rodrigo E
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1665-77. PubMed ID: 26329812
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation.
    Rivera-Caravaca JM; Camelo-Castillo A; Ramírez-Macías I; Gil-Pérez P; López-García C; Esteve-Pastor MA; Orenes-Piñero E; Tello-Montoliu A; Marín F
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281167
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
    Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
    J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease.
    Gibler WB
    Crit Pathw Cardiol; 2018 Jun; 17(2):53-68. PubMed ID: 29768312
    [No Abstract]   [Full Text] [Related]  

  • 45. Rivaroxaban in the Treatment of PICC-associated Upper Extremity Venous Thrombosis.
    Fan F; Zou Y; Zhang S; Zhang Y; Lan B; Song Q; Pei M; He L; Wu H; Du Y; Dart AM
    Clin Ther; 2017 Sep; 39(9):1882-1888. PubMed ID: 28823518
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of anticoagulation with rivaroxaban in trauma and acute care surgery: Complications and reversal strategies as compared to warfarin therapy.
    Myers SP; Dadashzadeh ER; Cheung J; Alarcon L; Kutcher M; Brown JB; Neal MD
    J Trauma Acute Care Surg; 2017 Mar; 82(3):542-549. PubMed ID: 28045742
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.
    Beyer-Westendorf J; Schellong SM; Gerlach H; Rabe E; Weitz JI; Jersemann K; Sahin K; Bauersachs R;
    Lancet Haematol; 2017 Mar; 4(3):e105-e113. PubMed ID: 28219692
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data.
    Hernandez I; Zhang Y
    Am J Cardiovasc Drugs; 2017 Feb; 17(1):37-47. PubMed ID: 27637493
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of low-dose anticoagulation therapy on peripheral artery disease: insights from the VOYAGER trial.
    Fukaya E; Leeper NJ
    Cardiovasc Res; 2020 Oct; 116(12):e156-e158. PubMed ID: 32980875
    [No Abstract]   [Full Text] [Related]  

  • 50. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
    Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI
    Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment.
    Ten Cate H; Guzik TJ; Eikelboom J; Spronk HMH
    Cardiovasc Res; 2021 Jul; 117(9):2030-2044. PubMed ID: 32931586
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of rivaroxaban on routine coagulation screening tests using commonly used reagents.
    Platton S; Bowles L; MacCallum P
    Br J Haematol; 2017 Nov; 179(3):511-513. PubMed ID: 27392166
    [No Abstract]   [Full Text] [Related]  

  • 53. Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    Windecker S; Tijssen J; Giustino G; Guimarães AH; Mehran R; Valgimigli M; Vranckx P; Welsh RC; Baber U; van Es GA; Wildgoose P; Volkl AA; Zazula A; Thomitzek K; Hemmrich M; Dangas GD
    Am Heart J; 2017 Feb; 184():81-87. PubMed ID: 27892890
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
    Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA
    N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.
    Howe Z; Naville-Cook C; Cole D
    J Thromb Thrombolysis; 2019 Feb; 47(2):280-286. PubMed ID: 30449001
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens.
    Providência R; Grove EL; Husted S; Barra S; Boveda S; Morais J
    Thromb Res; 2014 Dec; 134(6):1253-64. PubMed ID: 25457584
    [TBL] [Abstract][Full Text] [Related]  

  • 58. External applicability of the COMPASS trial: the Western Denmark Heart Registry.
    Würtz M; Olesen KKW; Thim T; Kristensen SD; Eikelboom JW; Maeng M
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):192-199. PubMed ID: 30916315
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Peri-Interventional Management of Direct Oral Anticoagulants - Balancing Benefits and Risks].
    Dülgeroglu J; Schmidt D
    Praxis (Bern 1994); 2018 Apr; 107(9-10):485-493. PubMed ID: 29690851
    [No Abstract]   [Full Text] [Related]  

  • 60. [Contemporary approaches to determine the duration of anticoagulant therapy for venous thromboembolism].
    Lobastov KV
    Khirurgiia (Mosk); 2019; (5):94-103. PubMed ID: 31169827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.